(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
New findings suggest atmosphere could exist on exoplanet TOI-561b - 25 Leisure activities That Work on Emotional well-being
- 3A Manual for Well known Western television Series
- 4UN estimates over 2,000 Sudanese pregnant women have fled el-Fasher to escape conflict
- 5James Webb Space telescope spots 'big red dot' in the ancient universe: A ravenous supermassive black hole named 'BiRD'
- When preventable infections turn deadly behind bars | The Excerpt
- An Investigate of 6 Creative Specialty Mixed drinks
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- Smartwatches: Remain Associated and Dynamic
- Heart disease risk greater for women with a common condition they may not be aware they have
- How Would You Like to Deal with Your Funds?
- The most effective method to Pick the Ideal Lab Precious stone Wedding band
- Best Wellness Tracker Keep You On target
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
